HYDROXYCARBAMIDE

Clinical Indication

Myeloproliferative disorders

Comments

Full SCA

Date of classification

January 2010

Review date

August 2016

Amber FULL SCA

Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.